Document Detail


Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis.
MedLine Citation:
PMID:  20512996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONCLUSION: Activation of isolated KCs produced Cys-LTs. Infusion of Cys-LTs increased portal pressure and, vice versa, treatment with montelukast reduced portal pressure in rat liver cirrhosis. Therefore, montelukast may be of therapeutic benefit for patients with portal hypertension.
Authors:
Christian J Steib; Manfred Bilzer; Mark op den Winkel; Susanne Pfeiler; Anna C Hartmann; Martin Hennenberg; Burkhard Göke; Alexander L Gerbes
Related Documents :
1354676 - Long-term haemodynamic effects of a 4-week regimen of nipradilol, a new beta-blocker wi...
16274836 - Histological-hemodynamic correlation in cirrhosis-a histological classification of the ...
11875586 - Comparative effects of nitroglycerin on intestinal vascular capacitance and conductance.
3943776 - Isosorbide dinitrate in experimental portal hypertension: a study of factors that modul...
9502566 - Nicardipine for hypertensive emergencies in children with renal disease.
10347266 - The hemodynamics of steal syndrome and its treatment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  51     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-06-17     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2086-96     Citation Subset:  IM    
Affiliation:
Department of Medicine II (Gastroenterology and Hepatology), Liver Center Munich, University of Munich, Grosshadern, Munich, Germany. christian.steib@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetates / therapeutic use*
Animals
Hypertension, Portal / drug therapy*,  etiology,  metabolism
Kupffer Cells / metabolism
Leukotriene Antagonists / therapeutic use*
Leukotrienes / metabolism*
Ligation
Liver / pathology
Liver Cirrhosis / complications*,  pathology
Male
Quinolines / therapeutic use*
Rats
Rats, Sprague-Dawley
Thioacetamide
Thromboxane A2 / metabolism
rho-Associated Kinases / metabolism
Chemical
Reg. No./Substance:
0/Acetates; 0/Leukotriene Antagonists; 0/Leukotrienes; 0/Quinolines; 57576-52-0/Thromboxane A2; 62-55-5/Thioacetamide; EC 2.7.11.1/rho-Associated Kinases; MHM278SD3E/montelukast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
Next Document:  Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibr...